SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 230 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $52,851,966 | -5.9% | 1,917,010 | +2.6% | 0.00% | 0.0% |
| Q2 2023 | $56,190,918 | -20.0% | 1,869,292 | -3.6% | 0.00% | -25.0% |
| Q1 2023 | $70,254,825 | -47.8% | 1,939,134 | -48.6% | 0.00% | 0.0% |
| Q4 2022 | $134,504,436 | +106.6% | 3,770,800 | +96.1% | 0.00% | 0.0% |
| Q3 2022 | $65,104,000 | +13.8% | 1,923,295 | -2.8% | 0.00% | +33.3% |
| Q2 2022 | $57,209,000 | -4.0% | 1,978,181 | +7.3% | 0.00% | 0.0% |
| Q1 2022 | $59,603,000 | +14.6% | 1,844,139 | +3.4% | 0.00% | +50.0% |
| Q4 2021 | $51,988,000 | +6.6% | 1,782,857 | -2.5% | 0.00% | -33.3% |
| Q3 2021 | $48,749,000 | -13.4% | 1,827,841 | +0.0% | 0.00% | 0.0% |
| Q2 2021 | $56,268,000 | +20.9% | 1,827,480 | +2.8% | 0.00% | 0.0% |
| Q1 2021 | $46,539,000 | +4.2% | 1,777,662 | +0.1% | 0.00% | 0.0% |
| Q4 2020 | $44,678,000 | +20.9% | 1,775,749 | +0.1% | 0.00% | 0.0% |
| Q3 2020 | $36,952,000 | -15.4% | 1,773,136 | -3.6% | 0.00% | 0.0% |
| Q2 2020 | $43,673,000 | +31.5% | 1,838,873 | -0.4% | 0.00% | 0.0% |
| Q1 2020 | $33,217,000 | -16.9% | 1,846,437 | +9.6% | 0.00% | 0.0% |
| Q4 2019 | $39,962,000 | -8.0% | 1,684,725 | +6.5% | 0.00% | 0.0% |
| Q3 2019 | $43,450,000 | -23.9% | 1,581,161 | -8.4% | 0.00% | -25.0% |
| Q2 2019 | $57,119,000 | -3.9% | 1,726,176 | +1.7% | 0.00% | -20.0% |
| Q1 2019 | $59,466,000 | +5.3% | 1,697,090 | -0.2% | 0.01% | 0.0% |
| Q4 2018 | $56,490,000 | -39.0% | 1,700,493 | -7.6% | 0.01% | -28.6% |
| Q3 2018 | $92,642,000 | -7.8% | 1,840,020 | +9.6% | 0.01% | -12.5% |
| Q2 2018 | $100,509,000 | +51.7% | 1,679,308 | +16.1% | 0.01% | +33.3% |
| Q1 2018 | $66,253,000 | +8.4% | 1,446,509 | -5.7% | 0.01% | +20.0% |
| Q4 2017 | $61,138,000 | +8.4% | 1,533,992 | +8.8% | 0.01% | 0.0% |
| Q3 2017 | $56,416,000 | -6.3% | 1,410,379 | +0.9% | 0.01% | 0.0% |
| Q2 2017 | $60,230,000 | +42.0% | 1,397,484 | +3.1% | 0.01% | +25.0% |
| Q1 2017 | $42,422,000 | +28.9% | 1,355,319 | +4.0% | 0.00% | +33.3% |
| Q4 2016 | $32,910,000 | +5.7% | 1,303,228 | +3.5% | 0.00% | 0.0% |
| Q3 2016 | $31,137,000 | +32.4% | 1,259,095 | +9.1% | 0.00% | 0.0% |
| Q2 2016 | $23,514,000 | +63.0% | 1,154,329 | +22.0% | 0.00% | +50.0% |
| Q1 2016 | $14,426,000 | -18.3% | 946,158 | -27.9% | 0.00% | 0.0% |
| Q4 2015 | $17,653,000 | -35.7% | 1,313,191 | -32.9% | 0.00% | -33.3% |
| Q3 2015 | $27,466,000 | +182.9% | 1,957,570 | +242.4% | 0.00% | +200.0% |
| Q2 2015 | $9,709,000 | +121.5% | 571,793 | +57.7% | 0.00% | – |
| Q1 2015 | $4,383,000 | +74.9% | 362,515 | +20.1% | 0.00% | – |
| Q4 2014 | $2,506,000 | +0.6% | 301,853 | +5.3% | 0.00% | – |
| Q3 2014 | $2,490,000 | -15.2% | 286,662 | +7.0% | 0.00% | – |
| Q2 2014 | $2,937,000 | +37.6% | 267,984 | +12.2% | 0.00% | – |
| Q1 2014 | $2,134,000 | +9.3% | 238,836 | -8.3% | 0.00% | – |
| Q4 2013 | $1,952,000 | +107.9% | 260,370 | +102.7% | 0.00% | – |
| Q3 2013 | $939,000 | +177.8% | 128,437 | +144.3% | 0.00% | – |
| Q2 2013 | $338,000 | – | 52,571 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |